FDA approves Novo Nordisk’s Fiasp fast-acting insulin

SILVER SPRING, Md. — The Food and Drug Administration has approved a new fast-acting mealtime insulin from Novo Nordisk. The agency granted approval to Fiasp to treat adults with diabetes.

The drug is a formulation featuring the company’s NovoLog insulin aspart developed with the aim of achieving properties that more closely match the natural physiological insulin mealtime response of someone without diabetes.

“We are very pleased that Fiasp will now also be available to people with diabetes in the United States,” Novo Nordisk EVP and chief science officer Mads Krogsgaard Thomsen said. “The fast action profile of Fiasp allows people with diabetes convenient timing in terms of when to take their insulin in connection with meals to achieve the optimal blood sugar control.”